December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Conversion rate of Pseudoexfoliation Syndrome to Pseudoexfoliation Glaucoma in a Population-based Study
Author Affiliations & Notes
  • SM Jeng
    Mayo Clinic Rochester MN
    Ophthalmology
  • RA Karger
    Mayo Medical School
    Mayo Clinic Rochester MN
  • DH Johnson
    Mayo Clinic Rochester MN
    Ophthalmology
  • DO Hodge
    Health Science Research
    Mayo Clinic Rochester MN
  • J Burke
    Health Science Research
    Mayo Clinic Rochester MN
  • MS Good
    Mayo Clinic Rochester MN
    Ophthalmology
  • Footnotes
    Commercial Relationships   S.M. Jeng, None; R.A. Karger, None; D.H. Johnson, None; D.O. Hodge, None; J. Burke, None; M.S. Good, None. Grant Identification: Support: Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SM Jeng, RA Karger, DH Johnson, DO Hodge, J Burke, MS Good; Conversion rate of Pseudoexfoliation Syndrome to Pseudoexfoliation Glaucoma in a Population-based Study . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the conversion rate of pseudoexfoliation syndrome (PEX) to pseudoexfoliation glaucoma (PEX-GL) in a population-based study. Methods: Using the Rochester Epidemiology Project database, we identified and reviewed the charts of all residents of Olmsted County, Minnesota newly diagnosed with PEX between 1976-1986. Patients diagnosed with PEX were followed until their last examination. Endpoints were treatment of ocular hypertension (TOHT) or the development of glaucoma (PEX-GL), defined as at least 2 of the following: intraocular pressure ≷ 21mmHg, glaucomatous optic nerve damage, or glaucomatous visual field defect. The probabilities for initiation of TOHT or conversion to PEX-GL were calculated by Kaplan-Meier estimates. Results: One hundred forty three eyes of 101 patients were newly diagnosed with PEX. Eighty-six eyes of 65 patients were started on treatment for ocular hypertension or developed glaucoma within 15 years of follow up. There were 50 females and 15 males with an average age of 76+/-10 years. The 5 year cumulative probability of PEX requiring treatment for ocular hypertension or converting to glaucoma was 57%(95% CI 47%-64%). At 10 and 15 years follow up, the cumulative probability of PEX requiring treatment for ocular hypertension or converting to glaucoma was identical at 64%(95% CI 54%-72%). Upon initial diagnosis of PEX, 27% of patients required treatment for ocular hypertension or were found to have glaucoma. Conclusion: In a geographically defined population of PEX patients, about one quarter required treatment for ocular hypertension or were found to have glaucoma upon presentation. An additional one third required treatment to control intraocular pressure or developed glaucoma over the next ten years. Patients with PEX have a 64% chance of requiring glaucoma treatment by 10 years.

Keywords: 352 clinical (human) or epidemiologic studies: natural history • 353 clinical (human) or epidemiologic studies: outcomes/complications • 354 clinical (human) or epidemiologic studies: prevalence/incidence 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×